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Abstract
Background: Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, with therapeutic applications in several
autoimmune and inflammatory diseases. Oral administration of this cytokine alone, or in combination with disease-
associated autoantigens could confer protection form the onset of a specific autoimmune disease through the induction
of oral tolerance. Transgenic plants are attractive systems for production of therapeutic proteins because of the ability
to do large scale-up at low cost, and the low maintenance requirements. They are highly amenable to oral administration
and could become effective delivery systems without extensive protein purification. We investigated the ability of
tobacco plants to produce high levels of biologically-active viral and murine IL-10.
Results: Three different subcellular targeting strategies were assessed in transient expression experiments, and stable
transgenic tobacco plants were generated with the constructs that yielded the highest accumulation levels by targeting
the recombinant proteins to the endoplasmic reticulum. The best yields using this strategy in T1 plants were 10.8 and
37.0 μg/g fresh leaf weight for viral and murine IL-10, respectively. The recombinant proteins were purified from
transgenic leaf material and characterized in terms of their N-glycan composition, dimerization and biological activity in
in vitro assays. Both molecules formed stable dimers, were able to activate the IL-10 signaling pathway and to induce
specific anti-inflammatory responses in mouse J774 macrophage cells.
Conclusion: Tobacco plants are able to correctly process viral and murine IL-10 into biologically active dimers,
therefore representing a suitable platform for the production for these cytokines. The accumulation levels obtained are
high enough to allow delivery of an immunologically relevant dose of IL-10 in a reasonable amount of leaf material,
without extensive purification. This study paves the way to performing feeding studies in mouse models of autoimmune
diseases, that will allow the evaluation the immunomodulatory properties and effectiveness of the viral IL-10 in inducing
oral tolerance compared to the murine protein.
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The production of biopharmaceuticals in transgenic
plants has become more and more attractive over the last
few years, primarily reflecting the low start-up and main-
tenance costs compared to fermenter-based production
platforms and the ability to scale up production rapidly
according to demand [1]. Plants can also be used as deliv-
ery systems for certain products, making extensive purifi-
cation unnecessary. This applies in particular to products
used for mucosal immunomodulation (e.g. oral vaccina-
tion or oral tolerance). Indeed, plant tissues are highly
suitable for oral administration, allowing the direct deliv-
ery of recombinant protein drugs to the gut-associated
lymphoid tissue (GALT) while encapsulating the proteins
and protecting them from digestion [2,3].
With these advantages in mind, we investigated the possi-
bility of using plants to produce the anti-inflammatory
cytokine interleukin-10 (IL-10), a multifunctional
cytokine from the alpha-helical bundle superfamily with
diverse effects on most hemopoietic cell types [4]. While
it plays a complex role in the immune system, the major
activities of IL-10 are to inhibit cytokine production by
macrophages and to suppress their accessory functions
during T-cell activation [5,6]. Since this causes the termi-
nation of inflammatory responses, IL-10 is widely consid-
ered as an immunosuppressive and anti-inflammatory
cytokine, and many investigations of IL-10 expression in
vitro, in animal models and in human patients have indi-
cated a significant role in inflammatory, malignant and
autoimmune diseases, highlighting the potential clinical
value of this cytokine [7]. Human IL-10 has been pro-
duced in stably transformed tobacco plants [8] and the
ability of plant-produced human IL-10 to induce anti-
inflammatory responses has also been demonstrated [9].
However, mammalian IL-10, including the human one,
also presents several immunostimulatory properties (e.g.,
activation of dendritic cells, NK cells, and some T cells)
which appear not to be negligible when IL-10 is used in
vivo to induce tolerance [10].
Interestingly, IL-10 has orthologs in several virus
genomes, and the IL-10 produced by Epstein-Barr virus
(vIL-10) is particularly closely related to its human coun-
terpart (71% and 84% identity at the nucleotide and
amino acid sequence levels, respectively) and binds to
both human and murine receptors [11]. Despite the
sequence similarity, vIL-10 exhibits primarily the
immune-inhibitory properties associated with the cellular
cytokine (e.g., suppression of Th1-polarized responses
and monocyte inhibition) but lacks many of the immu-
nostimulatory properties associated with the human IL-
10 (hIL-10) and murine IL-10 (mIL-10) [12]. This exacer-
bated inhibitory effect of vIL-10 makes it an even more
attractive therapeutic candidate for tolerance induction, as
the viral cytokine could have a profoundly different effect
on the outcome of an in vivo immune response compared
to hIL-10/mIL-10. [11].
One promising immunomodulatory application of IL-10
is to enhance the induction of oral tolerance to co-admin-
istered auto-antigens, leading to the prevention or treat-
ment of autoimmune diseases with lower doses of
tolerizing protein. We are particularly interested in the
induction of oral tolerance for the prevention of type 1
diabetes mellitus (T1DM) which could be achieved by
repeated oral administration of small doses of one of the
major auto-antigens associated with the disease, the 65-
kDa isoform of the enzyme glutamic acid decarboxylase
(GAD65). We have already reported the characterization
of transgenic tobacco plants producing immunoreactive
GAD65 [13], although feeding studies in a mouse model
have not yet been possible due to the low protein expres-
sion levels, requiring the consumption of unrealistically
large amounts of plant material in order to achieve an oral
tolerizing effect. However, simultaneous feeding with
plant material containing IL-10 could reduce the amount
of GAD65 necessary to induce oral tolerance. Addition-
ally, IL-10 induces the formation of T regulatory-1 cells
[10], and this should also drive the immune response
towards active rather than a passive tolerance, which
should in turn provide a more robust and long-lasting
protection from the onset of the autoimmune disease. A
comparative study, feeding either recombinant vIL-10 or
the recombinant endogenous mIL-10 together with the
GAD65 auto-antigen to NOD mice, would therefore allow
to evaluate and assess the outcome of the different immu-
nomodulatory properties of the viral cytokine in inducing
oral tolerance in the animal model, and to evaluate the
possibility of exploiting vIL-10 for the prevention of
T1DM.
Here we describe for the first time the production of vIL-
10 and mIL-10 in plants. Three different targeting strate-
gies were used to identify the best subcellular compart-
ment for IL-10 accumulation in tobacco leaves.
Characterization of the plant-derived cytokines confirmed
that tobacco plants can accumulate correctly-processed,
dimeric IL-10 and that the recombinant protein retains
the activity of its native counterpart. The impact of this
achievement on the oral delivery of auto-antigens pro-
duced in plant tissues is discussed.
Results
Investigation of different targeting strategies in transient 
expression assays
Three constructs each were designed for the mIL-10 and
vIL-10 transgenes, targeting the recombinant proteins to
three different sub-cellular localizations: (i) the endoplas-
mic reticulum (ER), achieved by retaining the native sig-Page 2 of 13
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retention (Fig. 1, ER-m/vIL-10) [14]; (ii) the plasma mem-
brane (IL-10 facing the apoplast), achieved using the
native signal peptide and adding the C-terminal hinge
and transmembrane domain from the human T-cell
receptor (Fig. 1, Apo-m/vIL-10) [15]; and (iii) the ER
membrane (IL-10 facing the cytosol), achieved by deleting
the native signal sequence and adding the C-terminal
cytochrome b5 (cytb5) membrane anchor domain (Fig-
ure 1, Cyt-m/vIL-10) [14,16,17]. These constructs, all
bearing a His6-tag at the C-terminus to facilitate protein
purification, were generated by PCR and inserted into the
plant expression vector pTRAk [18] placing the transgene
under the control of the CaMV 35S promoter with dupli-
cated enhancer (Figure 1). All plasmids were transferred
into Agrobacterium tumefaciens, and transient expression in
Nicotiana tabacum cv. Petit Havana SR1 leaves was carried
out at least three times for each construct by agroinfiltra-
tion. Analysis of IL-10 accumulation in leaves using a
sandwich enzyme-linked immunosorbent assay (ELISA;
Figure 2), showed that both mIL-10 and vIL-10 accumu-
lated to the highest levels in the ER (up to 10–16 μg/g
fresh leaf weight (FLW)). Furthermore, immunoblot anal-
ysis of leaf extracts indicated that the recombinant pro-
teins were correctly processed, as the molecular weights
were consistent with those of the mature native polypep-
tides (taking into account the C-terminal His6 and SEK-
DEL tags; data not shown).
Stable transformation of tobacco with constructs for ER 
retention
Based on the transient expression data, stable nuclear
transformation of N. tabacum cv. Petit Havana SR1 was
carried out using the ER-m/vIL-10 constructs. For each
construct, 40 transgenic plants were regenerated and the
amount of IL-10 in the leaves of the hemizygous T0 plants
was estimated by ELISA. For mIL-10, the best yield was
21.3 μg/g FLW, whereas the best yield of vIL-10 was 8.9
μg/g FLW, mirroring the results of the transient expression
assays. Transformants were fertile and the measurements
were repeated in T1 plants, resulting in accumulation lev-
els up to 37.0 μg/g FLW for mIL-10 and 10.8 μg/g FLW for
vIL-10. Transgenic plants expressing vIL-10 grew more
slowly than wild type plants and were stunted to an extent
that correlated with the amount of recombinant protein
accumulating in the leaves (see Additional file 1). The
plants expressing mIL-10 did not display any mutant phe-
notype.
Plant-derived mIL-10 and vIL-10 are dimeric
The biological activity of IL-10 depends strictly on its
dimeric state [19]. In order to determine whether or not
mIL-10 and vIL-10 were properly assembled into dimers,
T-DNA region of the pTRAk plant expression vector and gene cass ttes targeting murine and viral IL-10 to different subcellular l cationsFigure 1
T-DNA region of the pTRAk plant expression vector 
and gene cassettes targeting murine and viral IL-10 
to different subcellular locations. LB and RB, left and 
right border of the T-DNA; Pnos and pAnos, promoter and 
terminator of the nopaline synthase gene; nptII, coding 
sequence of the neomycin phosphotransferase gene; SAR, 
scaffold attachment region; P and pA, 35S promoter with 
duplicated enhancer and terminator of the cauliflower 
mosaic virus (CaMV) 35S gene; TL, 5' UTR of the tobacco 
etch virus (TEV); sp, native signal peptide; IL-10, mature IL-10 
sequence; His6, histidine tag; SEKDEL, ER retention signal; 
TcR, C-terminal hinge and transmembrane domain of the 
human T-cell receptor; cytb5, transmembrane domain of the 
rat cytochrome-b5. Not drawn to scale.
Comparison of IL-10 levels in leaves agroinfiltrated with the different targeting constructsFigure 2
Comparison of IL-10 levels in leaves agroinfiltrated 
with the different targeting constructs. N. tabacum cv. 
Petit Havana SR1 leaves were vacuum-infiltrated with A. 
tumefaciens carrying the different plant expression con-
structs. For each construct, three to four leaves from differ-
ent wild-type plants were infiltrated; they were incubated on 
wet filter paper for 3 d, with a 16-h photoperiod at ~20°C. 
Quantification of IL-10 accumulation levels in the leaf 
extracts was performed by sandwich ELISA. The gray and 
solid bars represent the data for the viral and murine IL-10, 
respectively; the localizations reported on the x axis refer to 
the constructs described in Figure 1. Values are the means ± 
SD of three independent experiments.Page 3 of 13
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genic tobacco leaves via immobilized-metal affinity chro-
matography (IMAC) on a nickel-nitrilotriacetic acid (Ni-
NTA) column, concentrated, and fractionated by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) under either reducing or non-reducing conditions.
Immunoblot analysis confirmed the correct molecular
weights of both viral and murine IL-10 (19 and 21 kDa,
respectively; Figures 3a and 3b, right panels). When sepa-
rated under non-reducing conditions, the plant-derived
vIL-10 predominantly formed stable dimers (Figure 3a,
left panel), whereas mIL-10 was partly dimeric and partly
monomeric (Figure 3b, left panel). Since commercial
mIL-10 also gives rise to a monomer band under these
conditions, this is most likely an artifact of the SDS-PAGE
method. This was confirmed by gel filtration analysis,
which showed that the plant-derived mIL-10 eluted as a
single peak with a profile corresponding to the size of the
dimeric form (Figure 3c).
Investigation of N-glycosylation and signal peptide 
cleavage
The mature mIL-10 polypeptide has two potential N-glyc-
osylation acceptor sites, whereas vIL-10 has a single site.
To determine the glycan composition, both plant-derived
proteins were digested with trypsin and analyzed by mass
spectrometry (MS). Despite the presence of a glycan
acceptor site at Asn127, the plant-derived vIL-10 was not
glycosylated. In contrast, mIL-10 was glycosylated, but
only one of the two potential acceptor sites was used, as is
the case for the native protein [20,21]. Unexpectedly for a
protein bearing a SEKDEL tag, oligo-mannose-type
(OMT) N-glycans accounted for only 46% of the total N-
glycan population, with Man7 being the most abundant
glycoform (Figure 4, N-glycan abbreviations according to
Proglycan [22]). Complex type N-glycans accounted for
44% of the total, with GnGnXF and GnGnX being the
most prominent. GnMX was present at lower levels, while
the other complex type N-glycans were found in only trace
amounts.
For both proteins, the identity of the N-terminal peptide
was established by tandem MS analysis. The sequence of
the mature mIL-10 polypeptide started with QYSRG while
vIL-10 started with TDQCD, confirming co-translational
ER translocation and correct cleavage of both signal pep-
tides, as predicted by the SignalP 3.0 server [23].
Biological activity of plant-derived mIL-10 and vIL-10
All the anti-inflammatory effects of IL-10 require the acti-
vation of signal transducer and activator of transcription 3
(STAT3), which acts downstream of the IL-10 receptor in
both mouse and human cellular models [11]. We there-
fore tested the ability of plant-derived mIL-10 and vIL-10
to phosphorylate the Tyr705 residue of STAT3. To exclude
possible interference from plant proteins co-purifying
with the recombinant IL-10 molecules, equal amounts of
wild type leaf material were subjected to the same purifi-
cation procedure on a Ni-NTA column, and the eluate was
used as a control in all biological activity assays. Stimula-
Assessment of IL-10 integrity and dimerizationFigure 3
Assessment of IL-10 integrity and dimerization. Viral 
(a) and murine (b) IL-10, purified from transgenic tobacco 
leaf extracts by IMAC, were analyzed by immunoblotting 
after separation by non-reducing (left panels) and reducing 
(right panels) SDS-PAGE. Commercial recombinant viral IL-
10 produced in E. coli (rvIL-10) or murine IL-10 produced in 
insect cells (rmIL-10) were used as controls, and different 
amounts of plant-derived IL-10 were loaded, as indicated on 
top of each lane. (c) Elution profile of plant-derived mIL-10 
from a Superdex 200 column showing a single peak which, 
compared to the elution volumes of standard reference mol-
ecules on the same columns (not shown), matches with the 
expected size of the dimer. Detection of IL-10 in the elution 
fractions was carried out by ELISA.Page 4 of 13
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doses of plant-derived mIL-10 and vIL-10 triggered STAT3
tyrosine phosphorylation within 15 min and in a dose-
dependent manner (Figure 5). The concentration of plant-
derived IL-10 required to elicit STAT3 tyrosine phosphor-
ylation to a degree comparable to that observed in
response to commercial mIL-10 (20 ng/ml) and vIL-10
(150 ng/ml) was 50 ng/ml for the murine protein (Figure
5a) and 500 ng/ml for the viral protein (Figure 5b). STAT3
phosphorylation resulted specifically from the presence of
recombinant IL-10, since control eluate from wild type
plant extracts had no detectable effect even at the highest
dose tested (Figure 5).
It has been reported that suppressor of cytokine signaling
3 (SOCS3) is one of the targets of murine IL-10 [24,25].
Indeed, SOCS3 mRNA and SOCS3 protein expression in
lipopolysaccharide (LPS)-stimulated J774 cells is
enhanced in the presence of commercial mIL-10 [26].
Similarly, purified plant-derived mIL-10 increased the
expression of LPS-induced SOCS3 mRNA (Figure 6a) and
SOCS3 protein (Figure 6b). Finally, we verified that the
plant-derived mIL-10 and vIL-10 were fully functional by
testing their inhibitory activity on the LPS-induced pro-
duction of tumor necrosis factor alpha (TNFα). The
amount of TNFα released into the culture supernatant of
J774 cells stimulated with LPS for 18 h was significantly
reduced in the presence of plant-derived mIL-10 to the
same extent observed with the commercial mIL-10 (Figure
7a). Similarly, the ability of plant derived vIL-10 to inhibit
LPS-induced TNFα production was equivalent to that of
its commercial counterpart (Figure 7b). Addition of con-
trol eluate from wild type plants had no effect on the J774
response to LPS, or the suppressive activity of IL-10 (Fig-
ure 7). These results confirmed that the inhibition of
TNFα production was dependent on the recombinant
cytokines, and not on any co-purified plant proteins.
Discussion
We set out to generate transgenic tobacco plants produc-
ing biologically-active vIL-10 and mIL-10 at levels suffi-
cient for raw transgenic leaf material to be used in animal
feeding studies. Such studies would compare the two ver-
sions of IL-10 as potential adjuvants for the induction of
oral tolerance to a co-fed auto-antigen in a mouse model
of type-1 diabetes or other autoimmune diseases.
The intracellular targeting of a recombinant protein often
has a significant effect on its yield and, in some cases, also
on its biological properties. Therefore, we targeted both
versions of IL-10 to three different subcellular compart-
ments – the ER, cytosol and apoplast – in order to assess
the impact on protein accumulation. Preliminary studies
of murine IL-10 transient expression driven by a PVX-
based system in N. benthamiana performed in our labora-
tory, had shown that the ER was by far the most suitable
compartment for mIL-10 accumulation compared to the
cytosol and the apoplast (ER-retained reached around 10
μg/g FLW; cytosolic and apoplastic expression was nearly
undetectable as determined by immunoblot analysis; data
Liquid chromatography-mass spectrometry (LC-MS) of the murine IL-10 glycosylated peptide EDNNCTHFPVGQSHMLLELRFigure 4
Liquid chromatography-mass spectrometry (LC-MS) of the murine IL-10 glycosylated peptide EDNNCTHF-
PVGQSHMLLELR. Murine IL-10 purified from stable transgenic leaf material was digested with trypsin and the peptides sub-
jected to LC-MS analysis. The spectrum of the glycosylated peptide is shown. See http://www.proglycan.com for an explanation 
of N-glycan abbreviations.Page 5 of 13
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ated with the plasma membrane are protected from deg-
radation in the cytosol and the apoplast [15,27,28], in this
work we used membrane anchors that allowed the recom-
binant proteins to be exposed to the apoplast or cytosol
while retaining them in the membrane, in the attempt to
increase the overall IL-10 accumulation levels. We evalu-
ated the three targeting strategies by transient expression
in tobacco leaves following agroinfiltration, since this
provides a reliable indication of performance much more
rapidly than the generation of stably transformed plants.
Despite the addition of membrane anchors to stabilize the
recombinant proteins in the cytosol and the apoplast,
both versions of IL-10 accumulated to the highest levels in
the ER, confirming our previous observations for mIL-10
and in line with what has been observed for hIL-10 stably
expressed in tobacco [8]. Many other recombinant pro-
teins have also accumulated to the highest levels in the ER
when different targeting strategies were compared [29-
Activation of STAT3 phosphorylation by murine and viral IL-10 produced in tobacco plantsFigure 5
Activation of STAT3 phosphorylation by murine and 
viral IL-10 produced in tobacco plants. STAT3 phos-
phorylation (STAT3-YP) was assessed by immunoblot analy-
sis on protein extracts of macrophage cells treated with 
increasing doses of plant-derived IL-10. (a) J774 cells were 
cultured for 15 min in the presence of eluate from wild type 
tobacco plants (lane 1; protein amount equivalent to the 150 
ng/ml sample of the mIL-10-producing tobacco line), 20 ng/ml 
of commercial mIL-10 produced in insect cells (lane 2) or 
increasing concentrations of plant-derived mIL-10 (lanes 3–
6); (b) J774 cells were cultured for 15 min in the presence of 
the eluate from purification of wild type tobacco plants (lane 
1; protein amount equivalent to the 500 ng/ml sample of the 
viral IL-10-producing tobacco line), 150 ng/ml of commercial 
vIL-10 (lane 2) or increasing concentration of plant vIL-10 
(lanes 3–6). Total cell extracts (50 μg) were separated by 
SDS-PAGE and immunoblots were performed as described in 
the Experimental Procedures section. One experiment rep-
resentative of two is shown. The blots were scanned on the 
Odyssey Infrared Imaging System at 700 and 800 nm. The rel-
ative STAT3-YP levels, as quantified by the Odyssey software 
and normalized for the total STAT3, are reported below 
each panel.
Effect of plant-derived murine IL-10 on LPS-induced SOCS3 mRNA and SOCS3 protein expressiFigure 6
Effect of plant-derived murine IL-10 on LPS-induced 
SOCS3 mRNA and SOCS3 protein expression. (a) 
J774 cells were stimulated for 2 h with 100 ng/ml of LPS 
alone or in combination with commercial mIL-10 (20 ng/ml), 
or plant mIL-10 (50 and 100 ng/ml). Non stimulated cells 
('medium') were included in the analysis to determine SOCS3 
basal expression levels. Total RNA was extracted and then 
analyzed for SOCS3 mRNA expression by real time RT-PCR. 
The graph shows the SOCS3 mRNA levels (mean ± SD) 
assayed in triplicate and normalized to GAPDH expression. 
(b) J774 cells were incubated for 18 h in the presence of LPS 
alone (lane 2) or in combination with 20 ng/ml commercial 
IL-10 (lane 3) or 50 ng/ml (lane 4) or 100 ng/ml (lane 5) plant 
derived mIL-10. Non stimulated cells ('medium') were 
included in the analysis to determine SOCS3 basal expres-
sion levels. Whole cell extracts (50 μg) were immunoblotted 
using anti-NH2 terminus SOCS3 antibody (upper panel) and 
antibodies specific for GAPDH (lower panel), followed by 
incubation with AlexaFluor 680 goat anti-rabbit and IRDye 
800 goat anti-mouse antibody. The relative levels of SOCS3 
protein, as quantified by the Odyssey software and normal-
ized for the total GAPDH content, are reported at the bot-
tom of each lane. The data shown in (a) and (b) are 
representative of two independent experiments. ** p < 
0.001.Page 6 of 13
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ment within the ER, favoring correct protein folding and
assembly, and high protein stability.
In T1 transgenic plants, the highest level of mIL-10 accu-
mulation was 37.0 μg/g FLW (0.6% total soluble protein
(TSP)) and the highest level of vIL-10 accumulation was
10.8 μg/g FLW (0.1% TSP). These yields fall into the 0.1–
1.0% TSP range typically observed for pharmaceutical
proteins produced in nuclear transgenic plants [32] and
are much higher than the 0.0055% TSP previously
reported for hIL-10, which is very similar in structure to
the murine and viral orthologs [8,33]. Surprisingly, the
expression of vIL-10 caused a stunted phenotype whose
severity correlated with the level of protein accumulation.
Further investigation is required to clarify the direct
impact of vIL-10 on plant development. The accumula-
tion of both versions of IL-10 increased between the T0
and T1 generations, indicating that protein yields are
partly dependent on the transgene copy number and/or
zygosity. Further strategies could be employed to boost IL-
10 accumulation, e.g. enhancing its stability through the
use of fusion tags or through the co-expression of interact-
ing molecules [34]. Nevertheless, the yields of both pro-
teins are already sufficient for feeding studies in the
mouse model. Indeed, on the basis of comparable experi-
ments [35], 2–10 μg of IL-10 per day should be sufficient
to elicit immunomodulatory effects and this would
require the administration of a few milligrams of lyophi-
lized plant tissue, which could be ingested by a mouse
without substantially interfering with its dietary needs [9].
The expression of a recombinant protein containing a
native signal peptide requires the signal peptide to be
interpreted correctly by the heterologous host cell, other-
wise the protein could be incorrectly cleaved or not
cleaved at all. This is especially relevant for pharmaceuti-
cal proteins, where imprecise cleavage could affect the
biological activity of the protein and might raise safety
concerns [36]. The mIL-10 signal peptide was correctly
processed in tobacco, as shown by sequencing the N-ter-
minal peptide of the mature protein, which had the same
QYSRE N-terminus previously reported for native mIL-10
[37]. There are at least two different N-terminal sequence
reported for vIL-10: QCDNF and TDQCD. The former is
claimed in several publications [38-40] and is most likely
based on the prediction first reported by Moore and col-
leagues [20]. The latter is predicted by the latest version of
the widely-used SignalP 3.0 Server [41,42], and is reported
in at least one publication [43]. Tandem MS analysis of
the N-terminal peptide of the purified vIL-10 produced in
tobacco showed the N-terminal sequence to be TDQCD,
in line with the prediction of the SignalP 3.0 Server. To
our knowledge, this is the first time that the N-terminal
amino acidic sequence of mature vIL-10 determined by
Inhibition of LPS-induced TNFα production by plant-derived murine and viral IL-10Figur  7
Inhibition of LPS-induced TNFα production by plant-
derived murine and viral IL-10. J774 cells were stimu-
lated for 18 h with IL-10 alone, LPS alone, or LPS plus IL-10. 
The eluate of the purification of wild type leaves (wt) was 
also included, alone or in combination with commercial IL-
10, to exclude the interference of plant proteins with the 
assay. TNFα secretion in the culture medium (med) was 
quantified by ELISA and is reported as pg/ml supernatant. 
Values are the means ± SD of four independent experiments 
for the murine IL-10 (a) and three independent experiments 
for the viral IL-10 (b). ** p < 0.001.Page 7 of 13
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by the expression in a eukaryotic cell.
Although vIL-10 is not glycosylated [44], both the native
and recombinant mIL-10 are heterogeneously N-glyco-
sylated at an acceptor site near the N-terminus [20]. This
glycosylation has no known influence on mIL-10 activity
[11], but the presence of plant complex type N-glycans on
therapeutic glycoproteins renders them potentially immu-
nogenic and thus raises safety concerns, particularly in the
case of parenteral administration. Even so the potential
immunogenicity of plant glycans may also be important
for orally administered proteins, especially in patients
with severe food allergies. The glycan modifications that
occur in the ER produce high-mannose-type N-glycans
that are conserved between mammals and plants, so the
use of a KDEL signal for ER retention not only increases
protein yields, but also prevents the addition of plant
complex type glycans. However, our N-glycan analysis
indicated that mIL-10, although carrying a SEKDEL tag, is
not efficiently retrieved to the ER, and is modified by
enzymes located in the trans-Golgi network [45,46]. In
addition, the presence of terminal GlcNAc residues on the
complex glycan structures would suggest that mIL-10
escaping the ER is secreted by the plant cell and not, for
example, directed to the vacuole [47]. The high efficiency
of ER retrieval has been documented for a number of
recombinant proteins produced in plants [48-50], but
there are also several examples of KDEL-tagged recom-
binant proteins containing complex type glycans, indicat-
ing that the retrieval system can be leaky and must be
evaluated on a case-by-case basis [51,52]. As immunoblot
analysis of the purified protein confirmed that the KDEL-
tag is still present (data not shown) and our protein yields
are not high enough to suggest saturation of the KDEL
retrieval machinery [53], the most likely explanation for
the presence of complex type N-glycans on mIL-10 is that
the tag is partially occluded following assembly of the IL-
10 dimer, and is not completely accessible to the KDEL
receptor. Localization studies will be performed in order
to complement the N-glycan analysis, and to clarify where
both versions of IL-10 precisely accumulate within the
plant cell, particularly since vIL-10 cannot be traced using
glycan structures.
Non-reducing SDS-PAGE followed by immunoblot anal-
ysis and (for mIL-10) gel filtration analysis confirmed that
both vIL-10 and mIL-10 assemble into dimers in tobacco
leaves. Moreover, it appears that the dimerization of both
plant-derived versions of IL-10 is more efficient than that
of their commercially produced counterparts. Since the
higher dimer/monomer ratio is consistent regardless of
the total amount of protein loaded onto the gel, we can
rule out the possibility that this is an artifact caused by
high protein concentration. It is also unlikely that the
presence of plant glycans is responsible, since vIL-10 is
not glycosylated. The most probable explanation is that
the presence of the C-terminal SEKDEL and His6 tags may
enhance the stability of the dimers. However, to confirm
this assumption, we would need to express non-tagged
versions of the proteins and compare the dimer/mono-
mer ratios. Increased stability of plant-derived IL-10 dim-
ers was also observed for hIL-10 by Menassa and
colleagues [33]. Interestingly, hIL-10 was not glycosylated
and the C-terminal tags had been cleaved from the plant-
derived hIL-10 by thrombin digestion, which should
remove all additional amino acids except a lysine and a
valine.
The ability of both vIL-10 and mIL-10 to form dimers
indicated that the recombinant proteins were likely to
retain their biological activity, a hypothesis we tested by
exposing LPS-stimulated J774 mouse macrophage cells to
different amounts of recombinant IL-10 and assaying the
effect on downstream components of the signaling path-
way. We observed a clear dose-dependent effect on STAT3
phosphorylation after treatment with both varieties of IL-
10, indicating that the plant-derived proteins properly
interacted with IL-10 receptor and initiated the signal
transduction cascade. Moreover, mIL-10 was able to
upregulate the expression of the intracellular negative reg-
ulator of cytokine responses, SOCS3. Most importantly,
given that IL-10 is best known for its ability to inhibit pro-
inflammatory cytokine and chemokine expression in LPS-
stimulated macrophages, our experiments demonstrated
that both mIL-10 and vIL-10 are able to inhibit the LPS-
induced production of TNFα. Higher doses of the plant-
derived proteins as compared to the corresponding com-
mercial IL-10 products were required, perhaps because of
the presence of the C-terminal SEKDEL and His6 tags. Nev-
ertheless, this will have no impact on the planning of
feeding studies since the dose of IL-10 necessary to
enhance oral tolerance needs to be determined empiri-
cally by administering different amounts of transgenic
plant material to the mice.
Conclusion
Taken together, these results clearly demonstrate that
tobacco plants can express the viral and murine IL-10
genes, process and assemble the corresponding proteins
into functional, biologically-active dimers. The accumula-
tion levels of both viral and murine IL-10 in tobacco
leaves are high enough to provide sufficient material for
oral administration in oral tolerance studies using the
available mouse models. This will allow to determine
whether simultaneous feeding with plant material con-
taining GAD65 and IL-10 could reduce the amount of
auto-antigen necessary to prevent the onset of T1DM, and
to comparatively evaluate the effectiveness of the viral and
murine IL-10 as immunomodulators.Page 8 of 13
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Plant transformation vectors
Six different constructs were generated using the polymer-
ase chain reaction (PCR) to amplify the murine and viral
IL-10 cDNA sequences from the pBluescriptSKII+mIL-10
[54] and pAAV-vIL-10 [55] plasmids, respectively, with
forward primers incorporating an NcoI restriction site at
the 5' end (for amplification of the complete IL-10 coding
region including the native signal peptide), or a BspHI site
(for amplification of the mature mIL-10 sequence) or an
XmnI site (for amplification of the mature vIL-10
sequence). The appropriate targeting and His6-tag
sequences were added by PCR in-frame to the 3' end of the
IL-10 coding region, and an XbaI site was created at the 3'
end of all the constructs. The 3' nucleotide sequence for
the ER-retained versions of IL-10 (ER-m/vIL-10) was 5 '-
CAT CAC CAT CAC CAT CAC TCT GAG AAA GAT GAG
CTC taa ACC GTC TAG AGC-3'. The sequence of the apo-
plast constructs (Apo-m/vIL-10) was 5'-GGT AGA GCA
GAC TGT GGC TTT ACC TCG GTG TCC TAC CAG CAA
GGG GTC CTG TCT GCC ACC ATC CTC TAT GAG ATC
CTG CTA GGG AAG GCC ACC CTG TAT GCT GTG CTG
GTC AGC GCC CTT GTG TTG ATG GCA ATG GTC AAG
AGA AAG GAT TTC CAT CAC CAT CAC CAT CAC taa ACC
GTC TAG AGC-3'. That of the cytosolic constructs (Cyt-m/
vIL-10) was 5'-CAT CAC CAT CAC CAT CAC GTC GAG
TCT AAT TCC AGT TGG TGG ACC AAC TGG GTG ATC
CCA GCC ATC TCA GCC CTG GTG GTA GCT CTG ATG
TAT CGC CTC TAC ATG GCA GAA GAT taa ACC GTC TAG
AGC-3'. In each case, the nucleotides encoding for the
His6-tag are in italic, the stop codons are shown in lower
case, and the XbaI sites are underlined. The resulting
amplification products were digested with the appropriate
restriction enzymes and inserted into the pTRAk binary
vector, a derivative of pPAM (GenBank: AY027531) [18].
The plasmids were electroporated into A. tumefaciens
strain GV3101::pMP90RK [56].
Transient and stable expression of IL-10 in tobacco
Agrobacterium-mediated transient expression (agroinfiltra-
tion) was carried out essentially as described by Kapila et
al. [57]. The bacterial cultures were adjusted to OD600 = 1
with 2× induction medium (10% (w/v) sucrose, 3.6% (w/
v) glucose, 8.6% (w/v) Murashige-Skoog salts) and water,
and induced for an additional 2 h with 200 μM acetosy-
ringone. N. tabacum cv. Petit Havana SR1 leaves were vac-
uum-infiltrated at 70 mbar for 20 min in the bacterial
suspension then placed in plastic trays with moistened
Whatman paper. The trays were sealed with Saran wrap
and incubated at 25°C with a 16-h photoperiod, 7000
Lux, for 3 d.
Stable transgenic tobacco (N. tabacum cv. Petit Havana
SR1) plants were produced using the leaf disc transforma-
tion method [58]. T0 plants were grown on Murashige-
Skoog medium containing 100 mg/l kanamycin prior to
transfer to soil in the glasshouse, and then selfed to pro-
duce the T1 generation. Transgenic T1 plants were also
selected on kanamycin-containing medium and main-
tained in soil.
Immunoblot analysis
Soluble proteins were extracted from leaf discs with three
volumes of PBS (pH 7.4) containing 0.05% (w/v) Tween-
20, 5 mM EDTA and 2% (w/v) polyvinylpolypyrrolidone
(PVPP). Equal volumes of the supernatant were either sep-
arated by SDS-PAGE on a 17% (w/v) gel prior to blotting,
or spotted directly onto a nitrocellulose membrane,
blocked for 1 h with 5% (w/v) non-fat milk and incubated
overnight at 4°C with either a rat anti-mouse IL-10 anti-
body (BD Pharmingen, San Diego, CA, USA) diluted
1:2000 or a rat anti-human IL-10 and viral IL-10 (BD
Pharmingen) antibody diluted 1:1000. The membrane
was then incubated for 1 h at room temperature with an
alkaline phosphatase (AP)-conjugated rabbit anti-rat
immunoglobulin G (IgG) (Sigma-Aldrich, St. Louis, Mo,
USA) diluted 1:5000. The signal was detected by incuba-
tion with nitroblue tetrazolium and 5-bromo-4-chloro-3-
indolyl phosphate (NBT-BCIP). Recombinant mIL-10
produced in insect cells (BD Pharmingen) and vIL-10 pro-
duced in Escherichia coli (R&D Systems, Minneapolis, MN,
USA) were used as standards.
Quantification of IL-10 by ELISA
Microtiter plates (High-binding; Greiner Bio-One GmbH,
Frickenhausen, Germany) were coated overnight at 4°C
with either a rat anti-mouse IL-10 antibody (BD Pharmin-
gen) diluted 1:1000 in 0.2 M sodium phosphate, pH 6.5,
or a rat anti-human IL-10 and viral IL-10 antibody (BD
Pharmingen) diluted 1:2000 in 50 mM sodium carbonate
buffer, pH 9.6. Wells were blocked with 1% (w/v) bovine
serum albumin (BSA) in PBS containing 0.05% (w/v)
Tween-20 (PBST) for at least 1 h. Samples diluted in PBS
were applied to the coated plates and incubated overnight
at 4°C. The corresponding biotinylated antibodies
(554465 and 554499; BD Pharmingen) were added to the
plates at 1:1000 dilution in PBST and incubated for 1 h at
room temperature. AP-conjugated streptavidin (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
was added to the wells at 1:2500 dilution in PBST, and
incubated for 30 min at room temperature before the sig-
nal was detected with p-nitrophenyl phosphate. After 15–
20 min, the signal was quantified by measuring the
absorbance at 405 nm. Ten two-fold serial dilutions of the
standards described in the previous section, starting from
a concentration of 50 ng/ml for the murine and 1 ng/ml
for the viral IL-10, respectively, were used as positive con-
trols, and the linear range of the dose-response curve
obtained was used for quantification of IL-10 in the sam-
ples. Extract from wild-type tobacco was used as negativePage 9 of 13
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bations.
Purification of IL-10 by IMAC
After removing the midrib, the leaf tissue was ground in a
mortar with liquid nitrogen and extracted with three vol-
umes of buffer (PBS, 10 mM ascorbic acid, 0.1% (w/v)
Tween-20, pH 6.0). Insoluble material was removed by
centrifugation (15 min, 15,000 × g, 4°C). The supernatant
was passed through a paper filter (#MN615, Macherey-
Nagel, Düren, Germany), adjusted to 500 mM NaCl, 5
mM imidazol, pH 8.0, and placed for 1 h on ice, gently
shaking. After another centrifugation step (30 min,
30,000 × g, 4°C), the clear supernatant was loaded on a
disposable column (Bio-Rad, Hercules, CA, USA) packed
with 1 ml Ni-NTA Superflow resin (QIAGEN, Hilden, Ger-
many) using a flow rate of approximately 2 ml/min. The
column was extensively washed with PBS (pH 8.0) con-
taining 500 mM NaCl and 5 mM imidazol to remove non-
specifically bound material and the IL-10 was eluted with
PBS containing 500 mM NaCl and 500 mM imidazol (pH
8.0). IL-10 fractions were pooled, dialyzed against water,
and lyophilized. Lyophilized material was then dissolved
in PBS (pH 7.4), the preparation was centrifuged to
remove residual insoluble material and IL-10 concentra-
tion in the supernatant was determined by ELISA.
Gel filtration
Gel filtration was performed using a Superdex 200 (10/
30) column (GE Healthcare, Uppsala, Sweden), with PBS
(pH 7.4) as the eluent and a flow rate of 0.35 ml/min.
Purified recombinant mIL-10 (450 ng) was loaded on the
column, and 1-ml fractions were collected for the elution
volumes 7–12 ml and 17–28 ml. Finally, 0.2-ml fractions
were collected from 12 to 17 ml. IL-10 was detected by
ELISA.
MS analysis of tryptic peptides and glycopeptides
Murine and viral IL-10 purified from leaf material by
IMAC were separated on a 17% (w/v) gel by SDS-PAGE
under reducing conditions, and the proteins were visual-
ized by Coomassie brilliant blue staining. The bands were
then excised, destained, carbamidomethylated, digested
with trypsin and extracted from gel pieces, as previously
described [59,60]. Subsequent fractionation of the pep-
tides by capillary reversed-phase chromatography, with
detection by a quadrupole time-of-flight (Q-TOF) Ultima
Global mass spectrometer (Waters Micromass, Manches-
ter, UK), was performed as described previously [59,61].
The MS data from the tryptic peptides were compared
with data sets generated by in silico tryptic digestion of the
recombinant protein sequences using the PeptideMass
program [59,60,62]. Sequences of the N-terminal pep-
tides were confirmed by tandem MS experiments. Data
were analyzed with MassLynx 4.0 SP4 Software (Waters
Micromass, Milford, MA, USA).
Characterization of IL-10 biological activity
The functional activity of murine and viral IL-10 produced
by tobacco plants was assessed in the mouse macrophage
cell line J774 (provided by Dr. V. Kruys, Université Libre
de Brussels, Belgium). Cells were resuspended in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 5% (w/v) low endotoxin fetal bovine serum (FBS)
(both from BioWhittaker, Walkersville, MD, USA), seeded
at a density of ~4 × 105/ml in 48-well tissue culture plates
and then stimulated with ultra-pure E. coli LPS (0111:B4
strain, InvivoGen, San Diego, CA, USA), in the presence or
absence of recombinant murine IL-10 (20 ng/ml, BD
Pharmingen), or recombinant viral IL-10 (300 ng/ml,
R&D Systems), or the indicated doses of murine and viral
IL-10 purified from tobacco plants (or corresponding neg-
ative control extracts from wild type leaves). The ability of
IL-10 to activate STAT3 and to upregulate SOCS3 protein
expression was evaluated by immunoblot analysis using
cell lysates prepared as previously described [63]. Briefly,
J774 extracts were prepared with lysis buffer (20 mM
HEPES, 420 mM, NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/
v) Nonidet-P40, 20% (v/v), glycerol, 1 mM DTT) contain-
ing inhibitors of proteases (5 μg/m leupeptin, 5 μg/ml
pepstatin, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml
α1-antitrypsin) and phosphatases (1 mM Na3VO4, 20 μM
phenylarsine oxide, 50 mM NaF). We then separated 50
μg of J774 lysates by SDS-PAGE and transferred the pro-
teins to a nitrocellulose membrane. For tyrosine-phos-
phorylated and total STAT3 detection, two-color
immunoblots were performed with rabbit anti-phospho-
STAT3 (Tyr705) and mouse anti-STAT3 124H6 antibodies
(both from Cell Signaling, Denver, MA, USA), respec-
tively, both diluted 1:1000. For SOCS3 and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), two-color
immunoblots were performed with rabbit anti-NH2 ter-
minus SOCS3 (1:150 dilution; Immuno-Biological Labo-
ratories, Tokio, Japan) and mouse anti-GAPDH (1:4000
dilution; Ambion, Austin, TX, USA) antibodies, respec-
tively. Detection was simultaneously carried out with
Alexa FluorR680 goat anti-rabbit antibody (1:5000 dilu-
tion; Molecular Probes™, Invitrogen, Carlsbad, CA, USA)
and IRDye™800-conjugated goat anti-mouse IgG (1:2500
dilution; Rockland, Gilbertsville, PA, USA) secondary
antibodies. Blotted proteins were detected and quantified
using the Odyssey infrared imaging system (LI-COR Bio-
sciences, Lincoln, NE, USA) and software provided by the
manufacturer.
SOCS3 gene expression was quantified by real-time RT-
PCR. Briefly, total RNA was extracted from 1 × 106 J774
cells using the RNeasy mini kit (QIAGEN), according to
the manufacturer's protocol. Reverse transcription wasPage 10 of 13
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time RT-PCR was performed in triplicate from 10 ng
cDNA using the SYBR Green real-time master mix "SYBR
Premix Ex Taq™" (Takara Bio Inc., Otsu, Shiga, Japan), in
the presence of 200 nM specific primer pairs purchased
from Invitrogen: SOCS3 forward 5'-CCTTTGTAGACT-
TCACGGCT-3', reverse 5'-TTTGGAGCTGAAGGTCTT-
GAG-3', GAPDH forward 5'-TGGCCTCCAAGGAGT
AAGAA-3', reverse 5'-GGTCTGGGATGGAAATTGTG-3'.
The reaction conditions performed by the DNA Engine
Opticon 2 System (MJ Research, Waltham, MA, USA),
were as follows: 95°C for 10 s, followed by 40 cycles of
95°C for 10 s and 60°C for 40 s. Data were calculated
with LinReg PCR 7.0 and Q-Gene software http://
www.BioTechniques.com and then expressed as mean
normalized expression (MNE) units after GAPDH nor-
malization.
Determination of TNFα levels in cell-free supernatants
was performed using a commercial ELISA kit (DY410;
R&D Systems), according to the manufacturer's instruc-
tions.
Statistical analysis
Statistical changes in TNFα production and SOCS3 mRNA
expression levels were determined using the one-way
ANOVA with α set to 0.05, according to the Newman-
Keuls test.
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